ICU患者低钙血症与平均动脉压对预后的关联
这项回顾性观察研究纳入北京协和医院ICU 2013年1月至2022年12月的4947例非高钙血症成人患者,按入住ICU后首个24小时平均离子钙(iCa)1.1 mmol/L界值分为低钙组(2160例,43.7%)与非低钙组。在4091例可纳入多因素分析的患者中,iCa与ICU死亡独立相关(OR 0.17;95% CI 0.04-0.79;P<0.05)。时间加权平均动脉压(TWA-MAP-0)和血压反应性参数(TWA-MAP-0/NE)分别中介ICU死亡的4.55%(95% CI 0.16-17%;P<0.05)和2.6%(95% CI 0.02-11%;P<0.05)。iCa与TWA-MAP-0正相关(ρ=0.17;P<0.01),与TWA-MAP-0/NE无显著关联(ρ=-0.07;P<0.01)。
要点
- 非高钙血症成人ICU患者中,首个24小时平均iCa与ICU死亡独立相关(OR 0.17;95% CI 0.04-0.79;P<0.05)。
- TWA-MAP-0和TWA-MAP-0/NE分别中介iCa与ICU死亡关联的4.55%(95% CI 0.16-17%;P<0.05)和2.6%(95% CI 0.02-11%;P<0.05)。
- iCa与TWA-MAP-0呈正相关(Spearman ρ=0.17;P<0.01)。
- iCa与TWA-MAP-0/NE无显著关联(Spearman ρ=-0.07;P<0.01)。
- 4947例患者中低钙血症(平均iCa≤1.1 mmol/L)占43.7%(2160例)。
适用人群与场景
- 非高钙血症成人患者,ICU入住后首个24小时内心离子钙数据可用,来自北京协和医院ICU 2013年1月至2022年12月收治患者。
- 按首个24小时平均iCa 1.1 mmol/L界值分为低钙组与非低钙组;多因素分析纳入4091例。
诊断标准与关键阈值
- 低钙血症分组标准:入住ICU后首个24小时平均离子钙(iCa)≤1.1 mmol/L。
- 血压参数:首个24小时时间加权平均动脉压高于0 mmHg(TWA-MAP-0)和高于65 mmHg(TWA-MAP-65)。
- 血压反应性参数:TWA-MAP-0除以首个24小时去甲肾上腺素输注的体重调整剂量(TWA-MAP-0/NE)。
研究设计与关键结果
- 研究类型:回顾性观察研究,单家综合医院ICU,纳入4947例非高钙血症成人患者,中位年龄61岁(四分位距49-71岁),女性2824例(57.1%)。
- 低钙血症(平均iCa≤1.1 mmol/L)2160例(43.7%)。
- 多因素分析(4091例)显示iCa与ICU死亡独立相关:OR 0.17(95% CI 0.04-0.79;P<0.05)。
- 中介分析:TWA-MAP-0中介ICU死亡比例为4.55%(95% CI 0.16-17%;P<0.05);TWA-MAP-0/NE中介比例为2.6%(95% CI 0.02-11%;P<0.05)。
- 相关性分析:iCa与TWA-MAP-0正相关(Spearman ρ=0.17;P<0.01);iCa与TWA-MAP-0/NE无显著关联(Spearman ρ=-0.07;P<0.01)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在非高钙血症ICU患者中,入住后首个24小时iCa与ICU死亡独立相关,该关联可能由TWA-MAP和血压反应性(TWA-MAP/NE)中介。
- 作者认为,iCa与TWA-MAP正相关,但iCa与TWA-MAP/NE之间未发现普遍关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to verify the relationship between hypocalcemia in the first 24 hours of ICU admission and mortality, we also hypothesized that blood pressure and blood pressure reactivity are associated with ionized calcium (iCa) and might have mediation effects in the iCa-mortality association.
DESIGN: Retrospective, observational study.
SETTING: ICUs in a general hospital.
PATIENTS: Nonhypercalcemia adult patients were divided into two groups based on mean iCa within the first 24 hours after ICU admission using a cutoff of 1.1 mmol/L.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: A total of 4947 patients from Peking Union Medical College Hospital between January 2013 and December 2022 were included in the study, with 2160 (43.7%) suffering from hypocalcemia. Overall, the median (interquartile range) age was 61 years (49-71 yr), with 2824 (57.1%) being female. Time-weighted average mean arterial pressure (TWA-MAP) above 0 and 65 mm Hg, respectively, during the first 24 hours were used to analyze the MAP of each patient and TWA-MAP/norepinephrine (TWA-MAP/NE) dose was calculated to examine blood pressure reactivity. Among 4091 patients eligible for multivariate analysis, iCa was independently associated with ICU mortality (odds ratio, 0.17; 95% CI, 0.04-0.79; p < 0.05). Both the blood pressure parameter (TWA-MAP above 0 mm Hg [TWA-MAP-0]) and pressure reactivity parameter (TWA-MAP-0/weight-adjusted dose of norepinephrine infusion in the first 24 hr after ICU admission [TWA-MAP-0/NE]) mediated the outcome of ICU mortality with a proportion of 4.55% (95% CI, 0.16-17%; p < 0.05) and 2.6% (95% CI, 0.02-11%; p < 0.05), respectively. TWA-MAP-0 correlated positively with iCa (Spearman rank test, ρ = 0.17; p < 0.01) while no significant association was found between iCa and TWA-MAP-0/NE (Spearman rank test, ρ = -0.07; p < 0.01).
CONCLUSIONS: In this retrospective study on nonhypercalcemia patients, iCa of the first 24 hours after admission was independently associated with ICU mortality, which was potentially mediated by TWA-MAP and blood pressure reactivity (TWA-MAP/NE). iCa was also positively associated with TWA-MAP, while no general relationship was found between iCa and TWA-MAP/NE.
参考来源
- Li FY, Chen Y, Zhou X, et al. Association of Hypocalcemia and Mean Arterial Pressure With Patient Outcome in ICU. Crit Care Med. 2025. PMID: 40013881. doi:10.1097/CCM.0000000000006602
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。